Tag
#XOMA
-
2026
-
XOMA – SCHEDULE 13D/A [Amend]
-
XOMA – 25-NSE
-
XOMA – 25-NSE
-
XOMA – 8-K
-
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
-
XOMA Royalty Announces Closing of Its Acquisition by Ligand
-
XOMA – 8-K
-
XOMA – DEFA14A
-
XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date
-
XOMA – DEFM14A
-
XOMA – 425
-
XOMA – 8-K
-
XOMA – SCHEDULE 13D/A [Amend]
-
XOMA – DEFA14A
-
XOMA – 8-K
-
XOMA – 10-Q
-
XOMA – SCHEDULE 13D/A [Amend]
-
XOMA – DEFA14A
-
XOMA – 8-K/A [Amend]
-
XOMA – DEFA14A
-
XOMA – 8-K
-
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
-
XOMA – DEFA14A
-
XOMA – DEF 14A
-
XOMA Royalty Declares Quarterly Preferred Stock Dividends